Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | DHODH | Q02127 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30730413 | 1.00 | POLB (0.56) | POLBGAACNR2ALDH1A1CYP1A2 | |
| SCHEMBL808798 | 0.88 | RAB9A (0.48) | POLBGAAALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL1153284 | 0.86 | ALDH1A1 (0.55) | POLBGAAALDH1A1CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL809087 | 0.84 | ALDH1A1 (0.53) | POLBGAAALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL11355645 | 0.82 | POLB (0.55) | POLBGAAALDH1A1HSD17B10NPC1 | |
| SCHEMBL18740426 | 0.81 | PKM (0.47) | POLBGAAALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL1193623 | 0.81 | ALOX5 (0.56) | POLBALDH1A1CYP1A2CYP3A4HSD17B10 | |
| SCHEMBL28157055 | 0.81 | RAB9A (0.51) | POLBGAAALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL5406287 | 0.81 | ALDH1A1 (0.49) | POLBGAAALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL5404742 | 0.81 | MEN1 (0.66) | POLBGAAALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117447339-A | Method for preparing alkyl substituted glycine derivative by driving visible light | 沈阳师范大学 | 2024-01-26 | — | — | CN | disclosed |
| CN-113668004-B | Method for electrochemical synthesis of non-natural amino acid derivatives | 浙江工业大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-113668004-A | Method for electrochemically synthesizing non-natural amino acid derivatives | 浙江工业大学 | 2021-11-19 | — | — | CN | disclosed |
| WO-2016086015-A1 | MYOGLOBIN-BASED CATALYSTS FOR CARBENE TRANSFER REACTIONS | UNIVERSITY OF ROCHESTER (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20110119775-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110105565-A1 | WATER SOLUBLE SMALL MOLECULE INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-05 | — | — | US | disclosed |
| US-7888332-B2 | Hydrazide-containing CFTR inhibitor compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888332-B2 | Hydrazide-containing CFTR inhibitor compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-02-15 | — | — | US | disclosed |
| EP-1740532-A4 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | UNIV CALIFORNIA (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090048207-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048207-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-02-19 | — | — | US | disclosed |
| US-7414037-B2 | cystic fibrosis transmembrane conductance regulator protein inhibitor; 2-naphthalenylamino-[(3,5-dibromo-2,4-dihydroxyphenyl)methylene][3-[4-(3-(PEG)n-thioureido)diphenyl)-thioureido]propanedioic acid dihydrazide (MalH-(PEG)nB); cystic fibrosis with forms of male infertility, secretory diarrhea | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414037-B2 | cystic fibrosis transmembrane conductance regulator protein inhibitor; 2-naphthalenylamino-[(3,5-dibromo-2,4-dihydroxyphenyl)methylene][3-[4-(3-(PEG)n-thioureido)diphenyl)-thioureido]propanedioic acid dihydrazide (MalH-(PEG)nB); cystic fibrosis with forms of male infertility, secretory diarrhea | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-08-19 | — | — | US | disclosed |
| CN-1960966-A | Hydrazide-containing CFTR inhibitor compounds and uses thereof | UNIV CALIFORNIA (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1740532-A2 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | The Regents of the University of California (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050239740-A1 | Hydrazide-containing CFTR inhibitor compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-10-27 | — | — | US | disclosed |
| WO-2005094374-A2 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239740-A1 | Hydrazide-containing CFTR inhibitor compounds and uses thereof | CFTR, ABCC5, SLC9A5 | POLB 4335/4885GAA 1207/4885CNR2 705/4885 |
| US-20110119775-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, ABCC5, SLC9A5 | POLB 4335/4885GAA 1207/4885CNR2 705/4885 |
| US-20090048207-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, ABCC5, SLC9A5 | POLB 4335/4885GAA 1207/4885CNR2 705/4885 |
| US-20110105565-A1 | WATER SOLUBLE SMALL MOLECULE INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, PKD1, PKD2 | POLB 3612/4885GAA 1537/4885CNR2 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.